Benitec Biopharma Q1 2026 Results: Net Loss of $12.9M, Loss Widens
Benitec Biopharma reported a net loss of $12.9 million for the quarter ended September 30, 2026, compared to $9.0 million in the prior year period, primarily driven by a significant increase in research and development expenses for their BB-301 program. The company maintained a strong liquidity position with $176.4 million in cash and cash equivalents to fund ongoing clinical development.
- Key figure
- Net loss $12.9M